Federico Cappuzzo, MD, PhD, Istituto Nazionale Tumori, Rome, Italy, talks on the latest developments in targeted therapies for lung cancer. There have been recent advances in targeting KRAS G12C, a notoriously difficult to treat alteration, with the targeting agents sotorasib and adagrasib demonstrating promising activity. The number of targeted agents is expanding, including for specific rearrangements such as in the RET gene, increasing the likelihood of improving patient survival. This interview took place during the virtual European Lung Cancer Congress 2022.
